Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
146.35
+0.74 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 23, 2023
Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023
June 23, 2023
Via
Benzinga
What 25 Analyst Ratings Have To Say About Sarepta Therapeutics
June 23, 2023
Via
Benzinga
Sarepta Wins FDA Approval For Highly Anticipated Gene Therapy
June 22, 2023
Sarepta will sell the Duchenne muscular dystrophy gene therapy under the brand name Elevidys.
Via
Investor's Business Daily
24 Analysts Have This to Say About Sarepta Therapeutics
June 06, 2023
Via
Benzinga
Canopy Growth, Avadel Pharmaceuticals And Other Big Stocks Moving Lower On Friday
June 23, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. GSR II Meteora Acquisition Corp. (NASDAQ: GSRM)...
Via
Benzinga
Sarepta Therapeutics' Therapy Becomes First To Score FDA Nod For Duchenne Muscular Dystrophy Gene Therapy
June 22, 2023
The FDA has granted accelerated approval to closely watched Sarepta Therapeutics Inc's (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged...
Via
Benzinga
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
June 22, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence
June 20, 2023
Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a
Via
Benzinga
NASDAQ:SRPT Shareholder Notice: Investigation over Possible Wrongdoing at Sarepta Therapeutics, Inc.
June 02, 2023
San Diego, CA -- (SBWIRE) -- 06/02/2023 -- An investigation was announced concerning possible breaches of fiduciary duties by certain directors at Sarepta Therapeutics, Inc.
Via
SBWire
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Leading the Way in Monday Trading Based on Percentage Gain
May 15, 2023
Via
Investor Brand Network
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
June 12, 2023
These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials.
Via
InvestorPlace
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
June 01, 2023
Shares surged into and out of the company's R&D Day, which included a surprise.
Via
Investor's Business Daily
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
June 01, 2023
The stock has now given back all of its 2023 gains as investors' fears mount.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Why Shares of Sarepta Therapeutics Are Dropping Wednesday
May 24, 2023
The FDA told the company that a review of a new therapy will take nearly a month longer.
Via
The Motley Fool
Why Sarepta Therapeutics Stock Is Skyrocketing Today
May 15, 2023
Investors are cheering a key FDA advisory committee vote.
Via
The Motley Fool
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 24, 2023
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.
Via
Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
May 24, 2023
Companies that don't make a lot of noise can still make you a lot of money.
Via
The Motley Fool
Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy
May 24, 2023
The company is working to treat Duchenne muscular dystrophy, a muscle-wasting disease.
Via
Investor's Business Daily
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
May 24, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Exposures
Product Safety
Why These 3 Nasdaq Stocks Buckled Today
May 16, 2023
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Via
The Motley Fool
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
May 16, 2023
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.
Via
MarketBeat
Exposures
Product Safety
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 15, 2023
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 15, 2023
Via
Benzinga
Why Is Sarepta (SRPT) Stock Up 29% Today?
May 15, 2023
Sarepta (SRPT) stock is on the move Monday as investors react to FDA advisors voting on its gene therapy for Duchenne muscular dystrophy.
Via
InvestorPlace
Sarepta Therapeutic Shares Surge 25% Following Favorable Gene Therapy Vote; Analyst Anticipates Huge Earnings Swing In 2024
May 15, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped nearly 24% on Monday morning after a panel of experts voted last Friday in favor of the company's DMD gene therapy for accelerated approval in...
Via
Benzinga
US Stocks Mixed; NY Manufacturing Activity Shrinks In May
May 15, 2023
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 75 points on Monday. Following the market opening Monday, the Dow traded down 0.23% to 33,224.02 while the NASDAQ rose 0.18% to...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 15, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.